Anagrelide (Agrylin) is a specific drug used for the treatment of secondary thrombocythemia associated with myeloproliferative neoplasms. It reduces the risk of thrombosis by lowering platelet count. In its clinical application, strict vigilance must be maintained against side effects such as cardiovascular toxicity and bleeding risk.

What Are the Side Effects of Anagrelide (Agrylin)?

Systemic Reactions

High incidence (≥5%): Weakness (23%), edema (21%), pain (15%), fever (9%), peripheral edema (9%), malaise (6%).

Some patients may experience flu-like symptoms or chills.

Cardiovascular System

Palpitations (26%) and tachycardia (8%) are the most common.

Other reactions: Chest pain (8%), arrhythmia, angina pectoris, orthostatic hypotension.

Digestive System

Diarrhea (26%), nausea (17%), and abdominal pain (16%) are the main manifestations.

Minor reactions: Vomiting (10%), abdominal distension (10%), decreased appetite (8%), dyspepsia (5%).

Nervous System

Headache (44%) has the highest incidence and may persist.

Others: Dizziness (15%), paresthesia (6%), drowsiness or insomnia.

Respiratory System

Dyspnea (12%) and cough (6%) are relatively common.

A small number of patients may experience epistaxis or pneumonia.

Severe Side Effects of Anagrelide (Agrylin) That Require High Vigilance

Cardiovascular Toxicity

QT interval prolongation: May lead to torsades de pointes. An electrocardiogram must be completed before medication.

Heart failure risk: The phosphodiesterase 3 (PDE3) inhibitory effect may exacerbate heart failure.

Clinical management: Avoid use in patients with congenital long QT syndrome.

Regular monitoring of electrolytes (especially blood potassium).

Pulmonary Hypertension and Pulmonary Toxicity

Pulmonary hypertension: Treatment can only be initiated after evaluating underlying cardiopulmonary diseases.

Interstitial lung disease: Manifested as progressive dyspnea, which may occur 1 week to several years after medication initiation.

Bleeding Risk

Combination with aspirin: The incidence of major bleeding events increases significantly.

High-risk groups: Patients using anticoagulants/antiplatelet drugs concurrently, and elderly patients.

Other Severe Reactions

Pancreatitis: Rarely reported in clinical trials.

Hepatotoxicity: Significant elevation of alanine transaminase (ALT)/aspartate transaminase (AST) may occur.

Tubulointerstitial nephritis: Rare, but renal function monitoring is necessary.

Precautions for Anagrelide (Agrylin) Use

Drug Interactions

QT-prolonging drugs: Chloroquine, clarithromycin, amiodarone, etc. (concurrent use is absolutely prohibited).

PDE3 inhibitors: Milrinone, cilostazol (may exacerbate cardiovascular side effects).

CYP1A2 inhibitors: Fluvoxamine, ciprofloxacin (may increase plasma drug concentration).

Medication in Special Populations

Pregnant women: Animal experiments have shown fetal growth retardation; the pros and cons must be weighed.

Lactating women: The drug can be excreted in breast milk; breastfeeding is prohibited during treatment.

Elderly patients: No dose adjustment is required, but enhanced cardiovascular monitoring is necessary.

Clinical Monitoring Requirements

Platelet count: Monitor every 2 days in the first week of treatment, then once a week until stable.

Cardiovascular assessment: An electrocardiogram is mandatory before treatment, and rechecks are required every 3-6 months thereafter.

Liver function: Monthly testing is required for patients with moderate to severe liver impairment.